This article was originally published in The Gray Sheet
FDA market go-ahead for the Ortho Summit system and processor makes it "the first automated system for blood and plasma screening cleared by the FDA," Cotelligent maintains. Developed in conjunction with Ortho Clinical Diagnostics, the system is designed to screen blood products for hepatitis and retroviruses, including HIV and HTLV. Initial installations are anticipated by year-end
You may also be interested in...
Babson recently raised $31m to accelerate commercialization of its blood testing “ecosystem,” developed with help from Siemens Healthineers and Becton Dickinson.
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.
Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.